Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Promiss Diagnostics, a US-based University of Wisconsin (UW)-Madison spinout developing ovarian cancer blood tests, has received a six-figure dollar sum from Warf Ventures, part of the university’s independent commercialisation unit, Wisconsin Alumni Research Foundation (Warf). Promiss has licensed Warf technology that applies machine learning to distinguish benign and malignant ovarian growths. Having already completed an initial study, Promiss will use the funding for further, retrospective testing of its approach and to file a pre-submission application with US regulator Food and Drug Administration. Warf Ventures is a $110m VC vehicle funded by Warf to supply grant and equity funding to technologies with UW-Madison origins.
